alpha synuclein aggregates in CSF; real-time quaking-induced conversion (RT-QuIC)
Jump to navigation
Jump to search
Indications
- evaluation of inherited Parkinson's disease
- 90% sensitivity & 80% specificity
- evaluation for prodromal alpha-synucleinopathies[2]
* high sensitivity & specificity in detecting underlying Lewy body pathology in those with mild cognitive impairment[3]
Clinical significance
- 90% sensitive & specific for development of Parkinson's disease or Lewy body dementia in patients with rapid eye movement sleep behavioral disorder[2]
- CSF alpha-synuclein seeding activity correlates with clinical features of Lewy body dementia[6]
- 89% sensitivity & 96% specificity for a diagnosis of Parkinson's disease[4]
- sensitivity for multiple system atrophy is 75%[4]
- sensitivity for idiopathic REM sleep behavior disorder is 64%[4]
- sensitivity of 92% & specificity of 85% for CSF seed amplification assay in differentiating Parkinson's disease patients from controls[5]
Procedure
- CSF real-time quaking-induced conversion (RT-QuIC)[1]
- CSF seed amplification assay of alpha-synuclein multiplexed with an enzyme-linked immunosorbent assay (ELISA)[5]
Notes
More general terms
Additional terms
Components
References
- ↑ 1.0 1.1 Garrido A, Fairfoul G, Tolosa ES et al. alpha-synuclein RT-QuIC in cerebrospinal fluid of LRRK2-linked Parkinson's disease. Ann Clin Transl Neurol 2019 May 9; 6:1024. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31211166 Free PMC Article
- ↑ 2.0 2.1 2.2 George J CSF Biomarker Flags Parkinson's Pathology Years Before Symptoms Appear. Strong sensitivity, specificity in early study. MedPage Today March 4, 2021 https://www.medpagetoday.com/neurology/parkinsonsdisease/91484
Iranzo A, Fairfoul G, Ayudhaya ACN et al Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurology 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33609478 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30449-X/fulltext
Zerr I RT-QuIC for detection of prodromal alpha-synucleinopathies Lancet Neurology 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33609466 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00036-3/fulltext - ↑ 3.0 3.1 Rossi M, Baiardi S, Teunissen CE et al. Diagnostic value of the CSF alpha-synuclein real-time quaking-induced conversion assay at the prodromal MCI stage of dementia with Lewy bodies. Neurology 2021 Jul 1; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34210822 PMCID: PMC8408510 Free PMC article https://n.neurology.org/content/97/9/e930
- ↑ 4.0 4.1 4.2 4.3 Poggiolini I et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 2021 Dec 11; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34894214 Free article https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awab431/6459775
- ↑ 5.0 5.1 5.2 Majbour N et al. Disease-associated alpha-synuclein aggregates as biomarkers of Parkinson disease clinical stage. Neurology 2022 Sep 12; [e-pub] isease-associated alpha-synuclein aggregates as biomarkers of Parkinson https://n.neurology.org/content/early/2022/09/12/WNL.0000000000201199
- ↑ 6.0 6.1 Coughlin DG et al. Association of CSF alpha-synuclein seeding amplification assay results with clinical features of possible and probable dementia with Lewy bodies. Neurology 2024 Aug 13; 103:e209656. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39013126 PMCID: PMC11238940 (available on 2025-08-13) https://www.neurology.org/doi/10.1212/WNL.0000000000209656